Acorda Therapeutics Company Profile (NASDAQ:ACOR)

About Acorda Therapeutics

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACOR
  • CUSIP: 00484M10
Key Metrics:
  • Previous Close: $25.30
  • 50 Day Moving Average: $21.40
  • 200 Day Moving Average: $21.73
  • 52-Week Range: $45,500,000.00 - $16.40
  • Trailing P/E Ratio: 101.20
  • Foreward P/E Ratio: 18.88
  • P/E Growth: 0.85
  • Market Cap: $1166.68B
  • Outstanding Shares: 45,500,000
  • Beta: 1.53
Profitability:
  • Net Margins: -4.38%
  • Return on Equity: -1.66%
  • Return on Assets: -0.88%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 2.01%
  • Quick Ratio: 1.67%
Additional Links:
Companies Related to Acorda Therapeutics:

Analyst Ratings

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (?)
Ratings Breakdown: 4 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $34.22 (35.27% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017Cantor FitzgeraldReiterated RatingNeutral -> PositiveView Rating Details
2/15/2017Goldman Sachs Group, Inc. (The)UpgradeSell -> NeutralView Rating Details
2/14/2017Cowen and CompanySet Price TargetBuy$60.00View Rating Details
2/9/2017J P Morgan Chase & CoSet Price TargetBuy$32.00View Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00View Rating Details
12/19/2016Janney Montgomery ScottInitiated CoverageNeutral$23.00View Rating Details
11/23/2016Leerink SwannReiterated RatingMarket PerformView Rating Details
8/25/2016Stifel NicolausReiterated RatingBuyView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00View Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
7/31/2015Canaccord GenuityReiterated RatingHold$32.00View Rating Details
6/22/2015MLV & Co.Set Price TargetBuy$58.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
4/22/2015Piper Jaffray CompaniesInitiated CoverageNeutralView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
2/14/2017Q416$0.11$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215$0.17$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.14$0.46$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.05$0.28$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.15$0.42$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.09$0.21$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
Current Year EPS Consensus Estimate: $0.98 EPS
Next Year EPS Consensus Estimate: $1.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.36)($0.36)($0.36)
Q4 20161($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acorda Therapeutics (NASDAQ:ACOR)
Insider Ownership Percentage: 8.00%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.90View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.00View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline
News IconAcorda Therapeutics Inc (ACOR) Upgraded to Neutral at Goldman Sachs Group, Inc (NASDAQ:ACOR)
eleganthomesinla.com - February 18 at 9:27 AM
News IconImpact of Brokerage Rating on Acorda Therapeutics, Inc.(ACOR) (NASDAQ:ACOR)
cloudhostinghq.net - February 18 at 9:27 AM
News IconThe Technicals For Acorda Therapeutics, Inc. (ACOR) Have Been Dissected (Brutally) - NY Stock News (NASDAQ:ACOR)
nystocknews.com - February 17 at 6:45 PM
News IconThe Acorda Therapeutics (ACOR) - Research Analysts' Recent Ratings Changes (NASDAQ:ACOR)
mundoaguaysaneamiento.net - February 16 at 8:24 PM
News IconThe Acorda Therapeutics (ACOR) - Research Analysts' Recent Ratings Changes (NASDAQ:ACOR)
mundoaguaysaneamiento.net - February 16 at 8:24 PM
seekingalpha.com logoAcorda Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:ACOR)
seekingalpha.com - February 16 at 8:24 PM
seekingalpha.com logoAcorda Therapeutics, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:ACOR)
seekingalpha.com - February 16 at 8:24 PM
biz.yahoo.com logoAcorda Therapeutics Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:ACOR)
us.rd.yahoo.com - February 16 at 8:24 PM
us.rd.yahoo.com logoAcorda Therapeutics upgraded by Goldman (NASDAQ:ACOR)
us.rd.yahoo.com - February 16 at 8:24 PM
capitalcube.com logoAcorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 (NASDAQ:ACOR)
us.rd.yahoo.com - February 16 at 8:24 PM
capitalcube.com logoAcorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 (NASDAQ:ACOR)
us.rd.yahoo.com - February 16 at 8:24 PM
thestreet.com logoBiotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co. - TheStreet.com (NASDAQ:ACOR)
www.thestreet.com - February 16 at 6:31 AM
streetinsider.com logoUPDATE: Goldman Sachs Upgrades Acorda Therapeutics, Inc ... - StreetInsider.com (NASDAQ:ACOR)
www.streetinsider.com - February 16 at 6:31 AM
investors.com logoAcorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC (NASDAQ:ACOR)
www.investors.com - February 16 at 6:31 AM
finance.yahoo.com logoEdited Transcript of ACOR earnings conference call or presentation 14-Feb-17 1:30pm GMT (NASDAQ:ACOR)
finance.yahoo.com - February 15 at 1:34 AM
News IconWatching the Levels: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Midway Monitor (NASDAQ:ACOR)
midwaymonitor.com - February 14 at 3:32 PM
reuters.com logoBRIEF-Acorda Therapeutics Q4 GAAP loss per share $0.07 - Reuters (NASDAQ:ACOR)
www.reuters.com - February 14 at 3:32 PM
seekingalpha.com logoAcorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:ACOR)
seekingalpha.com - February 14 at 3:32 PM
News IconToo Much Too Quickly? Stock Enters Overbought Range: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Aiken Advocate (NASDAQ:ACOR)
aikenadvocate.com - February 13 at 3:22 PM
seekingalpha.com logoAcorda Up, But Patent Battle Looms - Seeking Alpha (NASDAQ:ACOR)
seekingalpha.com - February 13 at 3:22 PM
4-traders.com logoAcorda Therapeutics Inc : Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial (NASDAQ:ACOR)
www.4-traders.com - February 11 at 8:18 PM
smarteranalyst.com logoJ.P. Morgan Provides Thoughts on Acorda Therapeutics Inc (ACOR) (NASDAQ:ACOR)
www.smarteranalyst.com - February 11 at 8:18 PM
streetinsider.com logoForm 8-K ACORDA THERAPEUTICS INC For: Feb 08 (NASDAQ:ACOR)
www.streetinsider.com - February 11 at 8:18 PM
News IconBRIEF-Acorda Therapeutics entered into settlement agreement with Apotex Corp, Apotex Inc on Feb. 8 (NASDAQ:ACOR)
www.businessinsider.com - February 11 at 8:18 PM
us.rd.yahoo.com logoIs This The Big Turnaround Acorda Needs? (NASDAQ:ACOR)
us.rd.yahoo.com - February 11 at 8:17 PM
us.rd.yahoo.com logoAcorda Parkinson’s Drug Succeeds In Phase 3 Study (NASDAQ:ACOR)
us.rd.yahoo.com - February 11 at 8:17 PM
thestreet.com logoAcorda Therapeutics Stock Surges on Clinical Trial Results (NASDAQ:ACOR)
us.rd.yahoo.com - February 11 at 8:17 PM
fool.com logoWhy Acorda Therapeutics Stock Is Jumping Today (NASDAQ:ACOR)
us.rd.yahoo.com - February 11 at 8:17 PM
streetinsider.com logoAcorda Therapeutics (ACOR) Entered Into Settlement Agreement with Apotex - StreetInsider.com (NASDAQ:ACOR)
www.streetinsider.com - February 10 at 8:26 PM
reuters.com logoBRIEF-Acorda Therapeutics entered into settlement agreement with Apotex Corp, Apotex Inc on Feb. 8 - Reuters (NASDAQ:ACOR)
www.reuters.com - February 10 at 3:22 PM
marketexclusive.com logoAcorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events - Market Exclusive (NASDAQ:ACOR)
marketexclusive.com - February 10 at 3:22 PM
biz.yahoo.com logoACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events (NASDAQ:ACOR)
biz.yahoo.com - February 10 at 3:21 PM
finance.yahoo.com logoBlog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial (NASDAQ:ACOR)
finance.yahoo.com - February 10 at 3:21 PM
finance.yahoo.com logoAcorda (ACOR) Catches Eye: Stock Gains 20.8% in Session (NASDAQ:ACOR)
finance.yahoo.com - February 10 at 3:21 PM
finance.yahoo.com logoA Loud Coaching Session on the Desk (NASDAQ:ACOR)
finance.yahoo.com - February 10 at 3:21 PM
investors.com logoAcorda Pops To 19-Week High On Strong Parkinson's Drug Trial (NASDAQ:ACOR)
www.investors.com - February 9 at 8:18 PM
streetinsider.com logoAcorda Therapeutics (ACOR) Phase 3 Trial CVT-30 Shows Statistically Significant Results - StreetInsider.com (NASDAQ:ACOR)
www.streetinsider.com - February 9 at 3:18 PM
News IconInvestor Update on Shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Midway Monitor (NASDAQ:ACOR)
midwaymonitor.com - February 8 at 8:24 PM
News IconCan This Stock Keep on Trucking? Lofty Projections For Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Aiken Advocate (NASDAQ:ACOR)
aikenadvocate.com - February 7 at 8:24 PM
businesswire.com logoAcorda Therapeutics to Present at Two Investor Conferences in ... - Business Wire (press release) (NASDAQ:ACOR)
www.businesswire.com - February 3 at 3:24 PM
finance.yahoo.com logoAcorda Therapeutics to Present at Two Investor Conferences in February (NASDAQ:ACOR)
finance.yahoo.com - February 3 at 3:24 PM
4-traders.com logoAcorda Therapeutics : Patent Issued for Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces (USPTO 9549893) (NASDAQ:ACOR)
www.4-traders.com - February 2 at 3:18 PM
finance.yahoo.com logoImplied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options (NASDAQ:ACOR)
finance.yahoo.com - February 2 at 3:18 PM
finance.yahoo.com logoAcorda to Host Conference Call to Discuss Fourth Quarter 2016 on February 14, 2017 (NASDAQ:ACOR)
finance.yahoo.com - January 31 at 3:21 PM
capitalcube.com logoAcorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : January 30, 2017 (NASDAQ:ACOR)
www.capitalcube.com - January 30 at 3:29 PM
News IconTechnical Review on Shares of Acorda Therapeutics Inc. (ACOR) - Sherwood Daily (NASDAQ:ACOR)
sherwooddaily.com - January 28 at 8:21 PM
News IconFocusing on the Numbers for Acorda Therapeutics Inc. (ACOR) - Market Point (NASDAQ:ACOR)
mtptnews.com - January 26 at 3:34 PM
News IconAurobindo Receives FDA Approval for Dalfampridine Extended-Release Tablets, 10 mg (NASDAQ:ACOR)
www.pharmalive.com - January 25 at 8:23 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma (NASDAQ:ACOR)
finance.yahoo.com - January 25 at 3:22 PM
marketexclusive.com logoCan Acorda Therapeutics Inc (NASDAQ:ACOR) Give Eli Lilly and Co (NYSE:LLY) A Run For Its Money In Migraine ... - Market Exclusive (NASDAQ:ACOR)
marketexclusive.com - January 24 at 3:38 PM

Social

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?

9 equities research analysts have issued 12 month price targets for Acorda Therapeutics' shares. Their predictions range from $22.00 to $60.00. On average, they expect Acorda Therapeutics' share price to reach $34.22 in the next twelve months.

When will Acorda Therapeutics announce their earnings?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • According to Zacks Investment Research, "Acorda’s flagship product Ampyra has been doing well and is expected to continue doing so. Promotional efforts and increasing awareness should help sales growth. Meanwhile, Acorda continues to work on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price outperformed the industry in past three months. However, with Ampyra facing several patent challenges, focus will remain on the company’s pipeline development efforts and ability to bring new products to market. Moreover, Acorda recently discontinued the development of Ampyra for post-stroke walking difficulties, which hurt investor sentiment. Estimates have remained stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/23/2017)

  • Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.99%), State Street Corp (3.58%), Dimensional Fund Advisors LP (3.27%), Perceptive Advisors LLC (1.56%), Broadfin Capital LLC (1.40%) and Armistice Capital LLC (0.93%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Andrew Blight, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Michael W Rogers, Richard P Batycky, Ron Cohen and Steven M Rauscher.

Who sold Acorda Therapeutics stock? Who is selling Acorda Therapeutics stock?

Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management, Armistice Capital LLC, Renaissance Technologies LLC, Guggenheim Capital LLC, Teachers Retirement System of The State of Kentucky, FMR LLC and Martingale Asset Management L P. Company insiders that have sold Acorda Therapeutics stock in the last year include Andrew A Hindman, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen and Steven M Rauscher.

Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?

Acorda Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, State Street Corp, Dimensional Fund Advisors LP, Two Sigma Investments LP, Russell Investments Group Ltd., A.R.T. Advisors LLC, Broadfin Capital LLC and Tudor Investment Corp Et Al.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Acorda Therapeutics stock cost?

One share of Acorda Therapeutics stock can currently be purchased for approximately $25.30.

Acorda Therapeutics (NASDAQ:ACOR) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Earnings History Chart

Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Dividend History Chart

Dividend Payments by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Last Updated on 2/19/2017 by MarketBeat.com Staff